T
T. Egenod
Publications - 17
Citations - 117
T. Egenod is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications receiving 55 citations.
Papers
More filters
Journal ArticleDOI
1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)
Marie Wislez,J. Mazieres,Armelle Lavolé,G. Zalcman,O. Carre,T. Egenod,R. Caliandro,Radj Gervais,Gaelle Jeannin,Olivier Molinier,Marie-Ange Massiani,Alexandra Langlais,Franck Morin,F. Le Pimpec Barthes,Laurent Brouchet,Jalal Assouad,Bernard Milleron,Diane Damotte,Martine Antoine,Virginie Westeel +19 more
Journal ArticleDOI
OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)
Olivier Molinier,Clarisse Audigier-Valette,Jacques Cadranel,Isabelle Monnet,José Hureaux,W. Hilgers,E. Fauchon,Elizabeth Fabre,Benjamin Besse,P. Brun,D. Coëtmeur,Elisabeth Quoix,Pierre Mourlanette,Fabrice Barlesi,S. Bordenave-Caffre,T. Egenod,P. Missy,Franck Morin,Denis Moro-Sibilot,Nicolas Girard +19 more
Journal ArticleDOI
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
Marie Wislez,Julien Mazieres,Armelle Lavolé,Gérard Zalcman,O. Carre,T. Egenod,Raffaele Caliandro,Catherine Dubos-Arvis,Gaelle Jeannin,Olivier Molinier,Marie Ange Massiani,Alexandra Langlais,Franck Morin,Françoise Le Pimpec Barthes,Laurent Brouchet,Jalal Assouad,Bernard Milleron,Diane Damotte,Martine Antoine,Virginie Westeel +19 more
TL;DR: Neoadjuvant durvalumab given as monotherapy was associated with an 89% complete resection rate and an MPR of 19%, and despite an unexpectedly high rate of postoperative deaths, this trial was able to show a significant association between MPR and DFS.
Journal ArticleDOI
1302PDIFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)
Nicolas Girard,C. Audigier Valette,Jacques Cadranel,Isabelle Monnet,J. Hureaux,W. Hilgers,E. Fauchon,Elizabeth Fabre,Benjamin Besse,P. Brun,D. Coëtmeur,E. Quoix,Pierre Mourlanette,Fabrice Barlesi,S. Bordenave-Caffre,T. Egenod,P. Missy,Franck Morin,D. Moro-Sibilot,Olivier Molinier +19 more
TL;DR: Real-life experience with nivolumab in patients with advanced Non-Small Cell Lung Cancer (NSCLC) and efficacy and safety of nivlumab and post-nivolumsab treatment in the French Expanded Access Program (EAP) are studied.
Journal ArticleDOI
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
Nadège Girard,Sigolène Galland-Girodet,V. Avrillon,Benjamin Besse,Mickael Duruisseaux,Jacques Cadranel,J. Otto,A Toby Prevost,Benoit Roch,Jaafar Bennouna,Karima Bouledrak,Marie Coudurier,T. Egenod,R. Lamy,Charles Ricordel,Denis Moro-Sibilot,Luc Odier,J. Tillon-Strozyk,Gérard Zalcman,P. Missy,Virginie Westeel,Simon Baldacci +21 more
TL;DR: Lorlatinib is a major treatment option for advanced refractory non-small-cell lung cancer (NSCLC) in treatment strategy as mentioned in this paper , which is a rare lung cancer with limited treatment options.